Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5234970 | 0.91 | DPP4 (0.35) | DPP4MAPK8PLA2G2AS1PR3LMNA | |
| SCHEMBL6701413 | 0.88 | PGR (0.40) | DPP4MAPK8S1PR3CNR2LMNA | |
| Hydrochloric Acid SCHEMBL5239932 | 0.88 | DPP4 (0.51) | DPP4MAPK8CNR2 | |
| SCHEMBL5230679 | 0.86 | DPP4 (0.36) | DPP4MAPK8CNR2LMNAKDM4E | |
| SCHEMBL5275959 | 0.85 | RORA (0.37) | DPP4MAPK8KDM4ESMN1; SMN2 | |
| SCHEMBL5231048 | 0.85 | TSHR (0.36) | DPP4PLA2G2AS1PR3KDM4ESMN1; SMN2 | |
| SCHEMBL5236611 | 0.85 | MAPK8 (0.34) | DPP4MAPK8S1PR3CNR2LMNA | |
| SCHEMBL6110129 | 0.85 | DPP4 (0.42) | DPP4MAPK8PLA2G2AS1PR3S1PR4 | |
| SCHEMBL5233633 | 0.85 | MAPK8 (0.36) | DPP4MAPK8S1PR3S1PR4S1PR1 | |
| SCHEMBL5237350 | 0.85 | RORA (0.37) | DPP4CNR2LMNAKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-7034039-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-25 | — | — | US | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | DPP4 2/4885MAPK8 2612/4885PLA2G2A 3137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.